S1PR1 and multiple sclerosis: A milestone in multiple sclerosis treatment has been reached by the discovery of fingolimod [58], first designated as FTY720, and its mechanism of action as an immunomodulatory drug acting on sphingosine-1-phosphate receptors [59,60,61].